drugset / Trial / NCT05312697
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
RandomizedSequentialOpen-labelTreatment
Summary
The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).
Timeline
- Start
- 2022-04-28
- Primary completion
- 2022-07-07
- Completion
- 2022-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Setrusumab | Monoclonal antibody | — | Intravenous |